

Special Issue

Research on Diagnosis, Treatment and Related Microbiota in Gastrointestinal Diseases

Message from the Guest Editors

The human gastrointestinal (GI) tract harbors a diverse and complex microbial community that plays a crucial role in health and disease. Advances in microbiome research have deepened our understanding of how gut microbiota influences the onset, progression, and treatment response of various GI disorders. Short-chain fatty acids (SCFAs), gut-derived metabolites with anti-inflammatory and immune-modulating properties, their dysregulation has been implicated in conditions such as IBD, irritable bowel syndrome (IBS), and even extraintestinal diseases, including immune checkpoint inhibitor (ICI)-induced colitis—a growing concern in cancer immunotherapy. This Special Issue aims to explore the latest research on microbiota-related mechanisms, diagnostic innovations, and treatment approaches in GI diseases. We welcome original research and review articles addressing microbiota-driven biomarkers, therapeutic modulation (e.g., probiotics, prebiotics, fecal microbiota transplantation), host-microbiome interactions, and precision medicine applications in gastroenterology and hepatology.

Guest Editors

Dr. Edoardo V. Savarino

Department of Surgery, Oncology and Gastroenterology, University of Padua, 35122 Padua, Italy

Dr. Brigida Barberio

Division of Gastroenterology, Department of Surgery, Oncology and Gastroenterology, University of Padua, 35121 Padua, Italy

Deadline for manuscript submissions

25 November 2025



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/232731

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)